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The term 'integrin' was proposed by Richard Hynes to
describe a family of integral membrane receptors thought to link
or "integrate" the cytoskeleton of one cell with that of another
cell or with the extracellular matrix [1]. Much has yet to be
learned about their intracellular connections, but the participa-
tion of these receptors in cell-matrix and cell-cell interactions
has been well documented in many recent reviews [2—9]. The
integrins comprise a superfamily of heterodimers composed of
noncovalently-associated a and /3 subunits, both of which are
transmembrane proteins (Fig. 1). Initially these receptors were
divided into three groups based on the sharing of a common /3
subunit (/3, /32 or /33) by various a subunits. These groups were
named the VLA proteins (/3 type), leukocyte integrins (CD1 1/
CD18 family; /32 type) and thirdly, the cytoadhesins (/33 type)
consisting of platelet GPIIbIIIa and the vitronectin receptor.
Now seven /3 subunits have been clearly defined, and genomic
analysis suggests that there may be at least 15 of these subunits.
In addition, new a subunits are in the process of being charac-
terized. A further complexity arises from variable splicing,
which so far has been localized to the cytoplasmic sequences of
/3 subunits. It was originally thought that the a subunits within
each group bonded faithfully to an individual /3 subunit, but it is
now apparent that alternative pairings are possible. Although
specificity for ligand is chiefly dictated by the a subunit,
association with different /3 subunits would appear to provide a
further level of specificity. For example, a of the vitronectin
receptor (VNR) can combine with /33 to recognize the matrix
proteins fibronectin, fibrinogen and vitronectin, with /3 to
recognize fibronectin and vitronectin and in a kidney cell line,
with /3 to recognise vitronectin only [10].
Structural relationships
A general feature of the a subunits is the location at the
N-terminus of seven homologous tandem sequences (I to VII)
of approximately 65 amino acids (Fig. 1). Three (V to VII) or
four (IV to VII) of these domains (depending on the particular
a subunit) contain putative divalent cation binding sites, As
integrin function is either Mg2 or Ca2 dependent, the divalent
cations must exert their effects by binding to these sites. Thus
LFA-l and VLA-2 bind Mg2, whereas VLA-5, a fibronectin
receptor, uses Ca2t The two metal ions can also act synergis-
tically to increase receptor function or alternatively, as in the
case of VLA-2 and LFA-l (Dransfield, Cabanas, Hogg, manu-
script submitted for publication), activity is negatively regu-
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lated by Ca2t The three leukocyte integrins, together with
VLA-1 and VLA-2 also contain an 'insertedlinteractive' or 'I'
region of about 200 amino acids, located between repeated
domains II and III, which is not homologous to these domains.
The I domain is homologous to particular sequences found in
other proteins—the three A domains of von Willebrand's factor
(vWF), two domains of cartilage matrix protein and comple-
ment factor B. The fact that these proteins bind collagen,
cartilage proteoglycan or complement component C3b suggests
that the I region may also be involved in similar ligand binding
although positive evidence for such specificity has been difficult
to obtain (R. Goldman and N. Hogg, unpublished observa-
tions).
Notable features of the extracellular domains of the major /3
subunits include a highly cross-linked four domain sequence,
containing 37 cysteines within a stretch of 190 amino acids, and
secondly, an area of high homology at the N-terminus which is
thought to participate in a/3 heterodimer formation and in
binding the tripeptide Arg-Gly-Asp (RGD). Less is known
about the other /3 subunits. However, it has been shown that /34
has a long cytoplasmic domain which is absent from the other /3
subunits, and that f35(f3) shares greatest homology with /33. 136
has been isolated using PCR primers corresponding to con-
served /3 sequences, but its a subunit partner remains unde-
fined. Finally, /37 is probably the human homologue of murine
/3p found in association with a4 and functions as a receptor on
lymphocytes for "homing" to Peyer's patch high endothelial
vessels.
Ligand binding
Ruoslahti and Pierschbacher, and Humphries showed that
many, but not all, of the receptors which bind to matrix
molecules recognize the tripeptide Arg-Gly-Asp (RGD) [11, 12].
Another unusual feature of some integrins is their ability to bind
to more than one ligand or counter receptor. The VNR has the
widest specificity with binding activity for vitronectin, fibrin-
ogen, von Willebrand's factor, fibronectin, thrombospondin
and bone sialoprotein. As all these VNR/matrix protein inter-
actions can be blocked using RGD peptides, VNR must have a
similar "binding footprint" for each protein. VLA-5, the clas-
sical fibronectin receptor, also seems to bind fibronectin via an
RGD sequence. However VLA-3 and VLA-4 recognize fi-
broriectin in a different manner, with the specificity of VLA-4
now known to be for another region of the fibronectin molecule,
called the CS-i domain. Further complexity arises from evi-
dence that the same receptor isolated from two different cell
types may have different binding specificities. For example,
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VLA-2 from platelets binds only collagen, but VLA-2 from
endothelial cells binds both collagen and laminin. These differ-
ences in receptor specificity which appear to depend on cell
type could be due to differences in membrane lipid composition,
variation in the cation usage, in differing a or /3 subunit splice
variants or the involvement of accessory molecules such as
gangliosides. The leukocyte integrins are not generally thought
to recognize the RGD motif. An exception may be the recog-
nition of iC3b by CR3/Mac-l. Human iC3b contains an RGD
sequence and it has been reported that peptides containing this
sequence inhibit the binding of iC3b to CR3.
Cross linking of RGD-containing peptides to /33 integrins
GPIIb/IIIa and VNR, indicates that both a and /3 subunits
contain sites to which RGD binds. For both receptors, —80% of
"cross linked" RGD was found to bind to the common f3
subunit at amino acids 61-203, with the highly conserved
sequence 108-128 earmarked as the location of actual RGD
binding. On the a subunit of GPIIb, the site of RGD binding has
been narrowed down to eleven residues within the second
(domain V) of the four putative cation binding domains. This
data is interpreted to indicate that the RGD binding sites on a
and /3 subunits may coordinate the binding of divalent cation
and ligand.
Other integrins bind to members of the immunoglobulin (Ig)
superfamily, thus providing another example of receptor/ligand
recognition occurring between superfamilies. The leukocyte
integrin LFA-l has specificity for intercellular adhesion mole-
cule-l (ICAM-l), a five Ig-like domain protein, and for ICAM-2
whose two Ig-like domains have —30% identity to the two most
distal domains of ICAM-1 [13]. As might be expected, evidence
based on domain deletion studies suggests that LFA-l interacts
with the first two domains of ICAM-1. A second integrin VLA-4
has specificity for another Ig family member, termed vascular
cell adhesion molecule (VCAM), which has two splice variants
called VCAM-l (6 Ig domains) and VCAM-2 (7 Ig domains).
VLA-4 also recognizes the matrix molecule fibronectin and it is
of interest that the binding sites on VLA-4 for VCAM-1 and
fibronectin may be independent. Thus some of the diversity of
ligand binding could be accounted for by the presence of several
kinds of binding sites on the integrins.
Integrin function
For at least some integrins, binding to ligand with high avidity
is not constitutive and is determined by the state of activation of
the cell on which the receptor is located. How this binding
activity is regulated is a matter of present interest. As a model
system we have analyzed the reaction between integrin LFA-1
and its ligands ICAM-1 and ICAM-2. LFA-l is confined to
leukocytes, whereas expression of ICAM-1 is relatively wide-
spread (and can be further induced by cytokines), making it
necessary for the reaction between LFA-1 and ICAM-l to be
carefully regulated in order to prevent random cellular cluster-
ing or aggregation. Increased avidity of LFA-l for ICAM-l is
inducible after cross linking the CD3 molecules associated with
the "antigen-specific" T cell receptor on the T lymphocyte
membrane. Interestingly, the triggering of a number of other
membrane molecules also causes an increase in the avidity of
LFA-l for ligand. Thus, signals generated by cross linking or
occupancy of these molecules can be transmitted to the leuko-
cyte integrins, suggesting a common mechanism of activation
involving intracellular signal transmission, which has been
termed "inside-out" signalling. A second feature of the in-
crease in avidity of LFA-l/ICAM-l interaction, as induced by
the CD3 cross linking, is that it is transient, lasting only 10 to 20
minutes. Other integrins can also be activated in this manner.
Using CD3 cross-linked T cells, transient activation has been
obtained for VLA-4, VLA-5 and VLA-6. Furthermore, the
process appears not to be limited to integrin activation as the
avidity of another adhesion molecule, the selectin Mel-14/
LAM-l is increased by CD3 cross linking in lymphocytes and
by cytokine receptor occupancy in neutrophils.
Central to these phenomena is the question of integrin
activation and how it is regulated. There is evidence that the
avidity increase might occur in two ways. Receptor clustering
would give an increase in avidity of binding to ligand, simply by
increasing the opportunity for the interaction to take place.
Many in vitro models for analysis of leukocyte integrin activity
have made use of phorbol esters, which include among their
activities the binding to and stimulation of protein kinase C.
These agents are strong promoters of leukocyte-integrin binding
activity, suggesting that kinases act directly upon leukocyte
integrins or associated cytoskeletal proteins to induce altered
function. For example, co-capping of LFA-l and talin occurs
following phorbol ester treatment. This indicates that the cell
surface distribution of cytoskeletal-associated leukocyte inte-
grins differs from unassociated receptors, possibly causing
them to cluster at sites of adhesive interaction, providing a
mechanism for avidity regulation. However, there is also evi-
dence that control of leukocyte functional activity can occur as
a result of a change in conformation of the receptor. Such
changes potentially could control the affinity of binding of
individual receptor/counter receptor pairs. The use of monoclo-
nal antibodies defining activation states of the integrins such as
the /33 integrin, GPIIbIIIa, have indicated that alterations occur
ES—S-i
LARGE SMALL
CHAIN CHAIN
Protease cleavage 4(only some integrins) Transmembrane Cytoplasmic
domain domain
+
Fig. 1. Genera! structure of integrin a- and
(3-subunit heterodimer (including features
such as the I domain and protease cleavage
site seen only in some integrins). Reproduced
from Roitt IM, Delves PD: Encyclopedia of
Immunology. Philadelphia, Saunders, in
preparation. Used with permission.
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extracellularly which correlate with observed induction of
functional activity. Although the precise alterations following
after activation are not defined, they may involve conforma-
tional changes which alter the relationship between a and f3
subunits. Furthermore, the presence of putative divalent cation
binding domains on the a subunits and a requirement for Mg2
or Ca2 for functional activity suggests that interaction with
ligand requires binding of divalent cations to leukocyte inte-
grins.
We have characterized a monoclonal antibody (mAb) named
24 which has been shown to bind to a novel epitope present on
the a subunits of the three leukocyte integrins, LFA-l, CR3 and
p150,95, which are expressed by leukocytes [14, 151. The effect
of mAb 24 on leukocyte integrin function has been analyzed
using two systems which are leukocyte integrin-dependent,
namely antigen presentation by monocytes to T cells (LFA-1-
dependent) and f-Met-Leu-Phe stimulated chemotaxis of neu-
trophils (CR3-dependent) (Note added in proof). Both functions
were found to be inhibited by the presence of mAb 24, impli-
cating the epitope recognized as a functionally important region
of the leukocyte integrins. Recent work has centred around
activation of leukocyte integrins, using the 24 epitope as a
"reporter" of such activation, with the hope that an under-
standing might be gained as to how mAb 24 blocks integrin-
mediated events.
This has led to the finding of a second novel feature of the 24
epitope which is that its recognition in the intact heterodimer is
Mg2-dependent and for intact cells, expression parallels recep-
tor activity. We have therefore suggested that control of the
affinity of Mg2 binding represents a potential mechanism for
regulation of receptor function. As previously stated, cross
linking studies have shown that the RGD sequence recognized
in matrix proteins by the /33 receptors binds with the cation
binding domains, suggesting an association between presence
of divalent cation and ligand binding to integrin. In spite of the
fact that neither of the LFA-l ligands ICAM-l nor ICAM-2
possesses such an RGD sequence, we wondered whether mAb
24 would directly block binding of the receptors to ICAM-1 or
ICAM-2. However, the result has been that binding of LFA-1 to
ICAM-1 or ICAM-2 is unaffected by the presence of mAb 24
(Note added in proof). One suggestion would be that the mode of
binding of ligand by integrins may depend on the type of
integrin and/or target protein. This type of result further sup-
ports the idea that matrix molecules such as fibronectin, and Ig
superfamily members such as ICAM may be bound by integrins
in different ways.
Another mAb specific for the LFA-l a subunit (NKI-Ll6),
was found to cause receptor activation by binding to an
extracellular epitope of LFA-1 [16]. Although the negative
effects of mAb 24 on function cannot be explained by interfer-
ence with binding of integrin receptor to ligand, it is possible
that its inhibitory effects come from promoting activation in a
manner similar to NKI-Ll6. Addition of mAb 24 to many
normal cell types caused no activation of the leukocyte inte-
grins, assessed by increased aggregate formation or enhanced
binding to ICAM-1 expressing targets. Thus mAb 24 does not
induce receptor activation. However, if mAb 24 was added to
cells which were capable of aggregating because of constitu-
tively activated integrins or were undergoing activation after
treatment with phorbol esters, then mAb 24 enhanced this
activity (Note added in proof). Thus the mAb was able to
promote activation which was already underway. A plausible
explanation for this behavior came from another set of experi-
ments, in which the CD3/TcR cross linking model of transient
LFA-l/ICAM-1 adhesion was used [17]. These experiments
have indicated that mAb 24 may be locking LFA-1 in the high
avidity or adhesive mode of ICAM-l binding and preventing
receptor/ligand de-adhesion (Note added in proof). Why tran-
sient adhesion between LFA-l and ICAM-1 is important for
progress in an immune response is not yet certain. It may be
simply a logistical problem, allowing access of large numbers of
T cells to antigen presenting cells for a brief period of time.
Alternatively, there is present interest in the possibility that
LFA- 1 mediates crucial intracellular signalling required for the
T cell programming leading to proliferation. These issues are
currently under investigation. Whether this type of transient
activation is a general feature of the functioning of all integrins
has still to be determined.
Note added in proof
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